<p>MiMedx Group, Inc（納斯達克代碼：MDXG - 免費報告）- 北方證券的投資分析師在 4 月 17 日星期五發布的研究報告中下調了 MiMedx Group 2026 年第三季度每股收益（EPS）預期。北方證券分析師 C. Byrnes 現在預計該公司本季度每股收益為$0.00，低於之前預測的$0.03。MiMedx Group 當前全年的每股收益共識預期為$0.30。北方證券還對 MiMedx Group 2026 年第四季度的每股收益預期為$0.01。</p>
<p>MiMedx Group（納斯達克代碼：MDXG - 獲取免費報告）最近一次發佈財報是在 2 月 25 日星期三。該公司報告本季度每股收益為$0.14，超出分析師共識預期的$0.09，超出幅度為$0.05。該公司本季度的收入為 1.181 億美元，而分析師預期為 1.0678 億美元。MiMedx Group 的淨利潤率為 11.60%，股本回報率為 29.37%。</p>
<p>其他一些分析師也對 MDXG 發表了看法。花旗集團在 2 月 23 日星期一的研究報告中開始覆蓋 MiMedx Group 的股票，並給予該公司 “市場表現優於大盤” 的評級。Weiss Ratings 在 12 月 29 日星期一的研究報告中重申了對 MiMedx Group 股票的 “持有（c）” 評級。華爾街 Zen 在 2 月 28 日星期六的研究報告中將 MiMedx Group 的股票評級從 “強力買入” 下調至 “買入”。瑞銀集團在 2 月 23 日星期一的研究報告中設定了 MiMedx Group 股票的目標價為$10.00。最後，Lake Street Capital 在 1 月 20 日星期二的研究報告中將 MiMedx Group 股票的目標價從$12.00 下調至$10.00，並給予該公司 “買入” 評級。六位分析師對該股票給予了買入評級，一位分析師對該公司的股票給予了持有評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價為$9.17。</p>
<p><strong>閲讀我們關於 MiMedx Group 的最新報告</strong></p>
<h2>MiMedx Group 股價下跌 0.3%</h2>
<p>MiMedx Group 的股票在週一開盤價為$3.41。該公司的速動比率為 3.92，流動比率為 4.32，債務與股本比率為 0.06。該公司的 50 日移動平均價格為$4.46，200 日移動平均價格為$5.85。該公司的市值為 5.0662 億美元，市盈率為 10.66，貝塔值為 1.65。MiMedx Group 的 52 周低點為$3.31，52 周高點為$7.99。</p>
<h2>MiMedx Group 的機構交易</h2>
<p>幾家機構投資者和對沖基金最近增加或減少了對 MDXG 的持股。SG Americas Securities LLC 在第一季度將其在 MiMedx Group 的持股增加了 28.6%。SG Americas Securities LLC 目前擁有 241,881 股該公司的股票，價值$955,000，在此期間又增持了 53,836 股。World Investment Advisors 在第四季度新購入了 MiMedx Group 的股份，價值約為$173,000。Virtu Financial LLC 在第四季度新購入了 MiMedx Group 的股份，價值約為$78,000。Invesco Ltd.在第四季度將其在 MiMedx Group 的持股增加了 5.9%。Invesco Ltd.目前擁有 84,824 股該公司的股票，價值$574,000，在此期間又增持了 4,708 股。最後，Corient Private Wealth LLC 在第四季度將其在 MiMedx Group 的持股增加了 26.0%。Corient Private Wealth LLC 目前擁有 46,658 股該公司的股票，價值$316,000，在此期間又增持了 9,614 股。79.15% 的股票由機構投資者和對沖基金持有。</p>
<h2>MiMedx Group 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>MiMedx Group, Inc 是一家生物製藥公司，專注於開發、製造和營銷源自人類胎盤組織的再生生物材料產品。該公司的核心使命是利用羊膜和絨毛膜中的細胞外基質和生長因子來支持傷口癒合和外科應用。MiMedx 的產品線利用專有的淨化工藝，旨在保留原生組織特性，同時確保無菌和安全。</p>
<p>MiMedx 的主要產品包括以 EpiFix®和 AmnioFix®等品牌命名的羊膜/絨毛膜同種異體移植物，適用於急性和慢性傷口的治療，包括糖尿病足潰瘍、靜脈性腿部潰瘍和手術部位修復。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 MiMedx Group 更具投資價值</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 MiMedx Group 嗎？</h2>
<p>在考慮 MiMedx Group 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 MiMedx Group 並不在名單上。</p>
<p>雖然 MiMedx Group 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得投資。</p>
<p>查看這五隻股票</p>

MDXG

<p>北方證券的投資分析師已將 MiMedx Group（納斯達克代碼：MDXG）2026 年第三季度每股收益（EPS）預估從 0.03 美元下調至 0.00 美元。市場共識對該公司全年收益的預估為每股 0.30 美元。MiMedx Group 最近報告的第四季度每股收益為 0.14 美元，超出預期。目前該股票的評級為 “適度買入”，目標價格為 9.17 美元。MiMedx Group 專注於從人類胎盤組織中提取的再生生物材料產品，主要用於傷口癒合和外科應用</p>

<p>MiMedx Group, Inc (NASDAQ:MDXG - Free Report) - Investment analysts at Northland Securities lowered their Q3 2026 EPS estimates for shares of MiMedx Group in a research note issued on Friday, April 17th. Northland Securities analyst C. Byrnes now anticipates that the company will post earnings per share of $0.00 for the quarter, down from their previous forecast of $0.03. The consensus estimate for MiMedx Group's current full-year earnings is $0.30 per share. Northland Securities also issued estimates for MiMedx Group's Q4 2026 earnings at $0.01 EPS.</p>
<div class="lb-trans"><p>MiMedx Group, Inc（納斯達克代碼：MDXG - 免費報告）- 北方證券的投資分析師在 4 月 17 日星期五發布的研究報告中下調了 MiMedx Group 2026 年第三季度每股收益（EPS）預期。北方證券分析師 C. Byrnes 現在預計該公司本季度每股收益為$0.00，低於之前預測的$0.03。MiMedx Group 當前全年的每股收益共識預期為$0.30。北方證券還對 MiMedx Group 2026 年第四季度的每股收益預期為$0.01。</p>
</div><p>MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.05. The firm had revenue of $118.10 million during the quarter, compared to analyst estimates of $106.78 million. MiMedx Group had a net margin of 11.60% and a return on equity of 29.37%.</p>
<div class="lb-trans"><p>MiMedx Group（納斯達克代碼：MDXG - 獲取免費報告）最近一次發佈財報是在 2 月 25 日星期三。該公司報告本季度每股收益為$0.14，超出分析師共識預期的$0.09，超出幅度為$0.05。該公司本季度的收入為 1.181 億美元，而分析師預期為 1.0678 億美元。MiMedx Group 的淨利潤率為 11.60%，股本回報率為 29.37%。</p>
</div><p>A number of other analysts have also weighed in on MDXG. Citigroup started coverage on shares of MiMedx Group in a research note on Monday, February 23rd. They issued a &#34;market outperform&#34; rating for the company. Weiss Ratings reaffirmed a &#34;hold (c)&#34; rating on shares of MiMedx Group in a research note on Monday, December 29th. Wall Street Zen lowered shares of MiMedx Group from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, February 28th. UBS Group set a $10.00 price target on shares of MiMedx Group in a research note on Monday, February 23rd. Finally, Lake Street Capital reduced their price target on shares of MiMedx Group from $12.00 to $10.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday, January 20th. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $9.17.</p>
<div class="lb-trans"><p>其他一些分析師也對 MDXG 發表了看法。花旗集團在 2 月 23 日星期一的研究報告中開始覆蓋 MiMedx Group 的股票，並給予該公司 “市場表現優於大盤” 的評級。Weiss Ratings 在 12 月 29 日星期一的研究報告中重申了對 MiMedx Group 股票的 “持有（c）” 評級。華爾街 Zen 在 2 月 28 日星期六的研究報告中將 MiMedx Group 的股票評級從 “強力買入” 下調至 “買入”。瑞銀集團在 2 月 23 日星期一的研究報告中設定了 MiMedx Group 股票的目標價為$10.00。最後，Lake Street Capital 在 1 月 20 日星期二的研究報告中將 MiMedx Group 股票的目標價從$12.00 下調至$10.00，並給予該公司 “買入” 評級。六位分析師對該股票給予了買入評級，一位分析師對該公司的股票給予了持有評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價為$9.17。</p>
</div><p><strong>Read Our Latest Report on MiMedx Group</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 MiMedx Group 的最新報告</strong></p>
</div><h2>MiMedx Group Trading Down 0.3%</h2>
<div class="lb-trans"><h2>MiMedx Group 股價下跌 0.3%</h2>
</div><p>MiMedx Group stock opened at $3.41 on Monday. The company has a quick ratio of 3.92, a current ratio of 4.32 and a debt-to-equity ratio of 0.06. The firm has a 50-day moving average price of $4.46 and a two-hundred day moving average price of $5.85. The firm has a market capitalization of $506.62 million, a price-to-earnings ratio of 10.66 and a beta of 1.65. MiMedx Group has a 52-week low of $3.31 and a 52-week high of $7.99.</p>
<div class="lb-trans"><p>MiMedx Group 的股票在週一開盤價為$3.41。該公司的速動比率為 3.92，流動比率為 4.32，債務與股本比率為 0.06。該公司的 50 日移動平均價格為$4.46，200 日移動平均價格為$5.85。該公司的市值為 5.0662 億美元，市盈率為 10.66，貝塔值為 1.65。MiMedx Group 的 52 周低點為$3.31，52 周高點為$7.99。</p>
</div><h2>Institutional Trading of MiMedx Group</h2>
<div class="lb-trans"><h2>MiMedx Group 的機構交易</h2>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in MDXG. SG Americas Securities LLC raised its holdings in shares of MiMedx Group by 28.6% during the first quarter. SG Americas Securities LLC now owns 241,881 shares of the company's stock valued at $955,000 after acquiring an additional 53,836 shares during the period. World Investment Advisors acquired a new stake in shares of MiMedx Group during the fourth quarter valued at approximately $173,000. Virtu Financial LLC acquired a new stake in shares of MiMedx Group during the fourth quarter valued at approximately $78,000. Invesco Ltd. raised its holdings in shares of MiMedx Group by 5.9% during the fourth quarter. Invesco Ltd. now owns 84,824 shares of the company's stock valued at $574,000 after acquiring an additional 4,708 shares during the period. Finally, Corient Private Wealth LLC increased its stake in MiMedx Group by 26.0% in the 4th quarter. Corient Private Wealth LLC now owns 46,658 shares of the company's stock valued at $316,000 after buying an additional 9,614 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近增加或減少了對 MDXG 的持股。SG Americas Securities LLC 在第一季度將其在 MiMedx Group 的持股增加了 28.6%。SG Americas Securities LLC 目前擁有 241,881 股該公司的股票，價值$955,000，在此期間又增持了 53,836 股。World Investment Advisors 在第四季度新購入了 MiMedx Group 的股份，價值約為$173,000。Virtu Financial LLC 在第四季度新購入了 MiMedx Group 的股份，價值約為$78,000。Invesco Ltd.在第四季度將其在 MiMedx Group 的持股增加了 5.9%。Invesco Ltd.目前擁有 84,824 股該公司的股票，價值$574,000，在此期間又增持了 4,708 股。最後，Corient Private Wealth LLC 在第四季度將其在 MiMedx Group 的持股增加了 26.0%。Corient Private Wealth LLC 目前擁有 46,658 股該公司的股票，價值$316,000，在此期間又增持了 9,614 股。79.15% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>MiMedx Group Company Profile</h2>
<div class="lb-trans"><h2>MiMedx Group 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.</p>
<div class="lb-trans"><p>MiMedx Group, Inc 是一家生物製藥公司，專注於開發、製造和營銷源自人類胎盤組織的再生生物材料產品。該公司的核心使命是利用羊膜和絨毛膜中的細胞外基質和生長因子來支持傷口癒合和外科應用。MiMedx 的產品線利用專有的淨化工藝，旨在保留原生組織特性，同時確保無菌和安全。</p>
</div><p>MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.</p>
<div class="lb-trans"><p>MiMedx 的主要產品包括以 EpiFix®和 AmnioFix®等品牌命名的羊膜/絨毛膜同種異體移植物，適用於急性和慢性傷口的治療，包括糖尿病足潰瘍、靜脈性腿部潰瘍和手術部位修復。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than MiMedx Group</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 MiMedx Group 更具投資價值</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=MDXG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MiMedx Group Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 MiMedx Group 嗎？</h2>
</div><p>Before you consider MiMedx Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 MiMedx Group 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 MiMedx Group 並不在名單上。</p>
</div><p>While MiMedx Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MiMedx Group 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得投資。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

MiMedx 集團第三季度每股收益預期被 Northland Securities 下調